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ABSTRACT
Purpose Hyponatraemia is associated with signiﬁcant
morbidity and mortality. The objectives of this study were
to evaluate the investigation and management of
hyponatraemia and to assess the use of different
therapeutic modalities and their effectiveness in routine
practice.
Study design This multicentre, retrospective,
observational study was conducted at three acute NHS
Trusts in March 2013. A retrospective chart review was
performed on the ﬁrst 100 inpatients with serum sodium
(sNa) ≤128 mmol/L during hospitalisation.
Results One hundred patients (47 male, 53 female) with
a mean±SD age of 71.3±15.4 years and nadir sNa of
123.4±4.3 mmol/L were included. Only 23/100 (23%) had
measurements of paired serum and urine osmolality and
sodium, while 31% had an assessment of adrenal reserve.
The aetiology of hyponatraemia was unrecorded in 58% of
cases. The mean length of hospital stay was 17.5 days
with an inpatient mortality rate of 16%. At hospital
discharge, 53/84 (63.1%) patients had persistent
hyponatraemia, including 20/84 (23.8%) with sNa
<130 mmol/L. Overall 37/100 (37%) patients did not have
any treatment for hyponatraemia. Among 76 therapeutic
episodes, the most commonly used treatment modalities
were isotonic saline in 38/76 cases (50%) and ﬂuid
restriction in 16/76 (21.1%). Fluid restriction failed to
increase sNa by >1 mmol/L/day in
8/10 (80%) cases compared with 4/26 (15.4%) for
isotonic saline.
Conclusions Underinvestigation and undertreatment of
hyponatraemia is a common occurrence in UK clinical
practice. Therefore, development of UK guidelines and
introduction of electronic alerts for hyponatraemia should
be considered to improve clinical practice.
INTRODUCTION
Hyponatraemia, deﬁned as serum sodium (sNa)
concentration below 135 mmol/L, is the most
common electrolyte abnormality encountered in
hospitalised patients, with a reported incidence of
30–42%.1 2 Hyponatraemia is an independent risk
factor for mortality3 4 and is associated with an
increase in length of hospital stay5 and hospital
resource utilisation.6
Accurate diagnosis of hyponatraemia is necessary
to guide effective treatment. However, numerous
single-centre studies in the UK have consistently
reported underutilisation of appropriate biochemical
tests in the investigation of hyponatraemia.7–13 It is
unclear to what extent inadequate investigation of
hyponatraemia reﬂects UK clinical practice in
general. There is also a paucity of data about the util-
isation of different therapeutic modalities for hypo-
natraemia and their efﬁcacy in a real world setting.
This study describes current clinical practice in
three acute UK hospitals. The objectives were to
evaluate the investigation and management of
inpatient hyponatraemia and to assess the use of dif-
ferent therapeutic modalities and their effectiveness.
METHODS
Study design
This was a multicentre, retrospective, observational
study examining the investigation and management
of 100 consecutive inpatients with serum sodium
(sNa) ≤128 mmol/L.
Recruitment started on 1 March 2013 and ended
on 28 March 2013 when a total of 100 patients
were reached. It was conducted simultaneously at
three acute NHS Trusts in London: centre 1, an
850-bed teaching hospital; centre 2, including 850
beds across two teaching hospitals; and centre 3, a
450-bed district general hospital. None of the three
institutions had local guidelines for the manage-
ment of hyponatraemia.
Patient selection
We deﬁned inpatient hyponatraemia as an sNa con-
centration ≤128 mmol/L at any point during hospital
admission. Patients were identiﬁed through an auto-
mated laboratory database search. A cut-off of
128 mmol/L was selected because previous data from
this hospital cohort showed an upward inﬂection in
inpatient mortality below that threshold.3 Subjects
with hyperglycaemia were included only if their cor-
rected sNa was ≤128 mmol/L. If venous glucose was
15–24.4 mmol/L, sNa was corrected by 1.6 mmol/L
for every 5.6 mmol/L increase in glucose concentra-
tion above 7 mmol/L; if glucose was >24.4 mmol/L,
a correction factor of 2.4 mmol/L was used.14
Data collection
Hospital case notes, laboratory results, drug prescrip-
tion charts and discharge letters were retrospectively
reviewed for each patient after hospital discharge.
Data were collected on age, gender, speciality respon-
sible for each patient, drug history, admission to the
intensive care unit, length of hospital stay, outcome
of admission, investigations and documented cause
of hyponatraemia, sNa levels at various time points,
use of therapeutic modalities, sNa 24 and 72 h after
initiation of treatment, and sNa at hospital discharge.
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Adequate investigation of hyponatraemia should include clinical
assessment of volume status, measurement of paired serum and urine
osmolality and Na, thyroid function tests and serum cortisol measure-
ment. The effectiveness of treatment of hyponatraemia was assessed
by sNa concentration at hospital discharge. For the purpose of evalu-
ating the effectiveness of different treatment modalities, ‘clear failure’
of treatment was deﬁned as a total sNa increase of ≤3 mmol/L after
the 72 h period after initiation of therapy. Over-rapid correction of
hyponatraemia, known to risk osmotic demyelination syndrome,15 16
was deﬁned as an sNa increase of >12 mmol/L in 24 h.
Data analysis
All data were recorded on an Access database and then transferred
into an Excel spreadsheet. Data were analysed separately for each
hospital and for all three hospitals together. Data were summarised
using descriptive statistics, with continuous variables being
expressed as mean±SD, and categorical variables as percentages.
Adequacy of investigation was assessed by the percentage of
patients who underwent each of the recommended tests. The pro-
portion of patients with normonatraemia and different degrees of
hyponatraemia (mild/moderate/severe) was used to determine the
effectiveness of management of hyponatraemia. The percentage of
patients who had ‘clear failure’ and ‘over-rapid correction’ deter-
mined the effectiveness of each therapeutic modality.
RESULTS
Demographic characteristics
Across three hospitals in London, 100 patients (47 male, 53
female) were included with a mean±SD age of 71.3±15.4 years.
Centre 1 included 38 patients (19 male, 19 female with a mean age
of 73.6±15.1 years), centre 2 contributed 30 patients (13 male, 17
female aged 68.5±15.5 years) and centre 3 contributed 32 patients
(15 male, 17 female with a mean age of 70.4±15.4 years).
The mean sNa on admission was 128.1±7.1 mmol/L, and the
lowest sNa during hospitalisation was 123.4±4.3 mmol/L. In
terms of the time point of onset of hyponatraemia, 58/100
(58%) patients presented on admission with sNa ≤128 mmol/L
in comparison with 42/100 (42%) who developed sNa
≤128 mmol/L during hospitalisation.
Speciality distribution
There was a wide distribution of patients within different special-
ities: 81/100 (81%) patients were under the care of medical speci-
alities including geriatrics (18%), general medicine (11%),
respiratory (9%), gastroenterology (9%), oncology (6%), hepatol-
ogy (6%), cardiology (5%), infectious diseases (5%), endocrin-
ology (4%), nephrology (3%), neurology (3%) and rheumatology
(2%); 19/100 (19%) patients were under the care of surgical speci-
alities including general surgery (5%), urology (5%), orthopaedics
(4%), cardiothoracic surgery (3%) and gynaecology (2%).
Drug history
Of the 100 patients, 35 were taking ACE inhibitors, 23 loop diure-
tics, 22 thiazide diuretics, 15 selective serotonin reuptake inhibi-
tors (SSRIs), 14 potassium-sparing diuretics, 12 angiotensin-II
receptor antagonists, and 6 tricyclic antidepressants.
Outcome of admission
The inpatient mortality rate in our cohort was 16%. The mean
length of hospital stay was 17.5±14.8 days with 9/100 (9%) of
patients requiring admission to the intensive care unit.
Diagnostic work-up
Clinical assessment of volume status was documented in 62/100
(62%) cases, while paired serum and urine osmolality and Na
were measured in 23/100 (23%). Complete work-up was under-
taken in 18/100 (18%) patients, as shown in table 1.
Aetiology of hyponatraemia
The aetiology of hyponatraemia was unrecorded in the notes of
58/100 (58%) patients. Review of case notes was used to ascer-
tain the aetiology of hyponatraemia in the remaining 42/100
(42%) patients, as summarised in table 2. Syndrome of inappro-
priate antidiuretic hormone secretion (SIADH) was attributed to
drugs in three cases (SSRIs in two cases and mirtazapine in one
case), to malignancy in two cases (small cell lung cancer in one
case and chronic lymphocytic leukaemia in one case) and to
miscellaneous causes in two cases (SIADH after transsphenoidal
surgery and SIADH of unknown cause).
Only 6/11 (54%) patients diagnosed with SIADH had all the
essential tests performed, including clinical assessment of
volume status, measurement of paired serum and urine osmolal-
ity and Na, and assessment of thyroid and adrenal function.17 18
Effectiveness of treatment of hyponatraemia
Correction of sNa ≥130 mmol/L was observed in 70/84 (83.3%)
patients at some point during admission, but hyponatraemia with
sNa <130 mmol/L recurred in 6/84 (7.1%). A signiﬁcant propor-
tion of patients (53/84 equal to 63.1%) had persistent hypona-
traemia at discharge from hospital, as shown in table 3.
Utilisation of treatment modalities
Overall, 37/100 (37%) patients did not have any treatment for
hyponatraemia. Of the 63 patients treated for hyponatraemia, 53
received one therapeutic modality, 7 received two modalities, and
3 received three treatment modalities. First-line therapy was iso-
tonic saline in 34/63 (54%) cases, discontinuation of potentially
offending drugs in 16/63 (25.4%), ﬂuid restriction in 10/63
(15.9%), infusion of human albumin solution in 2/63 (3.2%), and
initiation of hydrocortisone replacement in 1/63 (1.5%) cases.
Second-line therapy was isotonic saline in 4/10 (40%) cases, ﬂuid
restriction in 4/10 (40%), and hypertonic saline in 2/10 (20%).
Only three patients received third-line treatment, including two
cases of ﬂuid restriction and one case of demeclocycline.
Potentially offending drugs were discontinued in 36/100
(36%) patients, with the most common being ACE inhibitors or
angiotensin-II receptor antagonists (18%), loop diuretics (15%),
Table 1 Investigation of patients with hyponatraemia
Total Centre 1 Centre 2 Centre 3
Investigation (N=100) (%) (N=38) (%) (N=30) (%) (N=32) (%)
Volume status 62 71.0 53.4 59.4
Serum osmolality 39 39.5 33.3 43.8
Urine osmolality 33 39.5 30.0 28.1
Urine Na 29 34.2 36.6 15.6
Paired osmolality–Na 23 26.3 26.7 15.6
Serum TSH 61 71.0 63.3 46.9
Serum cortisol 31 34.2 26.6 31.2
Full work-up 18 23.7 20.0 9.4
Expert input 16 13.1 13.3 21.8
TSH, thyroid-stimulating hormone.
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thiazide diuretics (10%), potassium-sparing diuretics (10%) and
SSRIs (3%).
In total, 76 episodes of treatment were recorded, which
included isotonic saline in 38/76 (50%) cases, drug discontinu-
ation in 16/76 (21.1%), ﬂuid restriction in 16/76 (21.1%),
hypertonic saline in 2/76 (2.6%), human albumin solution in
2/76 (2.6%), hydrocortisone replacement in 1/76 (1.3%) and
demeclocycline in 1/76 (1.3%) cases. Use of other drug therap-
ies for SIADH, such as tolvaptan, urea or combination of loop
diuretics with oral sodium chloride, was not recorded.
Effectiveness of isotonic saline and ﬂuid restriction
‘Clear failure’ of treatment with a total sNa increase of ≤3 mmol/L
after the 72 h period after initiation of therapy was recorded in 4/
26 (15.4%) patients treated with isotonic saline compared with 8/
10 (80%) individuals managed with ﬂuid restriction, as illustrated
in table 4. Fluid restriction was imposed on 16 patients with
various volumes prescribed per 24 h (1500 mL in 4 cases,
1000 mL in 9 cases, 750 mL in 1 case and 500 mL in 2 cases).
Hypertonic saline was used in two patients, with infusion of
1000 mL saline 1.8% over 18 h increasing sNa by 13 mmol/L, and
300 mL saline 1.8% over 8 h increasing sNa levels by 11 mmol/L.
DISCUSSION
We found that hyponatraemia was frequently underinvestigated,
underdiagnosed and suboptimally managed in routine practice
in three hospitals in London. Urine Na, the most important bio-
chemical test19 20 in investigation of hyponatraemia, was mea-
sured in less than one-third of cases. The underlying aetiology
of hyponatraemia, despite being essential to guide appropriate
treatment, was unrecorded in more than half of the cases. The
limited effectiveness of current management, with 63.1% of
patients being discharged with persistent hyponatraemia, was
not surprising considering the lack of treatment for hyponatrae-
mia in a substantial proportion of patients. Among patients
receiving treatment for hyponatraemia, isotonic saline or ﬂuid
restriction were most commonly used, with ﬂuid restriction
being ineffective in the majority of cases.
Similar results from all three hospitals indicate that insufﬁcient
diagnostic work-up and ineffective treatment of hyponatraemia
may reﬂect UK routine care in general. There are several possible
barriers to good clinical practice in this ﬁeld, such as the dimin-
ished provision of undergraduate and postgraduate education in
clinical chemistry in recent times,13 21 the lack of national guide-
lines, the absence of diagnostic algorithms and treatment path-
ways in most hospitals or their complexity where they exist, and
the limited therapeutic options with little evidence basis for the
treatment of SIADH. Besides demonstrating suboptimal standard
of care for hyponatraemia, we found that ﬂuid restriction, cur-
rently the ﬁrst-line treatment for SIADH, does not correct hypo-
natraemia in most cases. Potential reasons are poor patient
adherence because of thirst, inadequate rigour in the volume of
ﬂuid intake prescribed (which needs to be restricted to at least
500 mL/day less than urine output), and its questionable effect-
iveness per se given the limited evidence base behind its thera-
peutic value.20 22 Therefore, clinicians should pay more attention
to appropriate prescription and implementation of ﬂuid restric-
tion and should also have access to alternative therapeutic
options such as vaptans and urea.
In comparison with previous UK studies, we recorded a
higher frequency of performance of appropriate diagnostic tests.
In the subgroup of our cohort with a nadir sNa ≤125 mmol/L,
40.7% of patients had urine Na and 40.7% had serum cortisol
measured compared with 10–18.6%7–10 and 8–15.2%,7–9 11
respectively, reported in other UK series using the same cut-off.
It is unclear whether these ﬁndings represent a widespread
rather than a local improvement in the investigation of hypona-
traemia in recent years. Regarding the aetiology of hyponatrae-
mia, SIADH was reported in only a quarter of our cases, in
contrast with most studies suggesting it as the most common
cause;18 23 24 therefore, SIADH was probably underdiagnosed.
This study has provided insight into the contemporary investi-
gation and management of hyponatraemia in the UK. However,
it had a number of limitations. First and foremost, it could not,
by its design, test whether undertreatment of hyponatraemia
Table 3 Serum sodium (sNa) concentration at hospital discharge
SNa at discharge
Overall
N=84
Patients with sNa <125 mmol/L (%) 4.8
Patients with sNa 125–129 mmol/L (%) 19.0
Patients with sNa 130–134 mmol/L (%) 39.3
Patients with sNa ≥135 mmol/L (%) 36.9
Mean±SD sNa (mmol/L) 132.8±4.7
Table 4 Effectiveness of isotonic saline and fluid restriction in
correcting hyponatraemia in first 72 h
SNa correction after treatment
Isotonic saline
(N=26)
Fluid restriction
(N=10)
Mean±SD change in sNa (mmol/L) 7.3±5.0 2.8±3.2
Percentage of patients
sNa increase <2 mmol/L 7.7 30.0
sNa increase 2–3 mmol/L 7.7 50.0
sNa increase 4–8 mmol/L 50.0 10.0
sNa increase 9–12 mmol/L 19.2 10.0
sNa increase >12 mmol/L 15.4 0
Over-rapid correction of hyponatraemia (sNa increase of >12 mmol/L/day) was
recorded in 3/76 (3.9%) therapeutic episodes. All three patients, two treated with
isotonic saline and one with hypertonic saline, had an sNa increase of 13 mmol/L
within 24 h without any adverse neurological sequelae.
Table 2 Classification of cases according to documented aetiology
of hyponatraemia
Aetiology
Overall
(N=42), n (%)
Hypovolaemic 23 (54.7)
Gastrointestinal Na losses 9 (21.4)
Poor oral intake 7 (16.6)
Diuretics 6 (14.3)
Adrenal insufficiency 1 (2.4)
Euvolaemic 11 (26.2)
SIADH due to pneumonia 4 (9.5)
Drug-induced SIADH 3 (7.1)
Malignant SIADH 2 (4.8)
Miscellaneous causes 2 (4.8)
Hypervolaemic 8 (19.1)
Decompensated cirrhosis 4 (9.5)
Heart failure 4 (9.5)
SIADH, Syndrome of inappropriate antidiuretic hormone secretion.
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contributed to adverse patient outcomes and, more importantly,
whether correcting hyponatraemia could improve clinical out-
comes. Second, the small sample size and the fact that all three
hospitals are in London raise the question whether the ﬁndings
apply to UK clinical practice in general. Third, its retrospective
nature made accurate identiﬁcation of the cause of all cases
of hyponatraemia impossible. As a result, its ability to
evaluate the effectiveness of different therapeutic modalities was
limited because failure of treatment might sometimes reﬂect
misdiagnosis.
In conclusion, this study highlights the need to improve clinical
practice. It is essential to develop tools such as electronic alert
systems for severe hyponatraemia, similar to electronic
alerts for acute kidney injury already introduced in several NHS
hospitals.25–27 By highlighting hyponatraemia and referring to
intranet-based guidelines, electronic alerts could prompt optimal
investigation and treatment in a timely manner. Another innova-
tive model of care delivery with the potential to improve stand-
ard of care is the development of multidisciplinary hospital
‘hyponatraemia teams’ combining the expertise of endocrinolo-
gists, nephrologists, chemical pathologists and other physicians.
In addition, UK guidelines on management of hyponatraemia are
still needed despite the recent publication of clinical practice
guidelines by an expert panel22 and by a joint venture of the
European Society of Endocrinology with the European Renal
Association.20 The reason is that clinical practice and experience
in the UK differ from that in the USA22 and continental Europe20
with regard to the structure of the healthcare system and the
availability of treatment options, such as urea and vaptans.
Finally, we agree with the authors of both European and
US guidelines on the urgent need for studies evaluating the
effect of correction of hyponatraemia on patient-important out-
comes such as symptoms, quality of life, mortality and length of
hospital stay.20 22
Main messages
▸ Hyponatraemia is frequently underinvestigated and
underdiagnosed in UK clinical practice.
▸ Most patients are discharged with persistent hyponatraemia,
while a substantial proportion of them have not received
any treatment for hyponatraemia.
▸ Fluid restriction is often ineffective in correcting
hyponatraemia due to SIADH.
Current research questions
▸ Does correction of hyponatraemia improve patient outcomes
such as length of hospital stay and mortality?
▸ What would be the impact of measures such as introduction
of electronic alert systems or widespread provision of expert
input on management of inpatient hyponatraemia and
patient outcomes?
▸ What is the optimal treatment strategy for hyponatraemia
due to SIADH with regard to sodium correction and patient
outcomes?
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